AAB-003 (PF-05236812)

DRUG2 trials

Sponsors

Pfizer

Conditions

Alzheimer's Disease

Phase 1

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

CompletedNCT01193608

PfizerAlzheimer's Disease

Start: 2010-09-30End: 2013-10-31Updated: 2017-02-23

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

CompletedNCT01369225

PfizerAlzheimer's Disease

Start: 2011-07-31End: 2014-08-31Updated: 2017-03-10

Related Papers

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.

2016-03-0143 citations